Multiplex RNA-Guided Genome Engineering
US-2016168592-A1 · Jun 16, 2016 · US
Engineered enzyme
US11214781B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11214781-B2 |
| Application number | US-202117374628-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 13, 2021 |
| Priority date | Oct 22, 2018 |
| Publication date | Jan 4, 2022 |
| Grant date | Jan 4, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure provides a novel catalytically inactive MAD7 nuclease (dMAD7) that retains the ability to bind DNA in a sequence-specific manner. The MAD7 nuclease from which the dMAD7 has been derived was isolated from Eubacterium rectale.
First claim
Opening claim text (preview).
We claim: 1. A catalytically inactive CRISPR nuclease obtained from Eubacterium rectale MAD7 (dMAD7) having the amino acid sequence SEQ ID NO: 2 that retains the ability for sequence specific binding a bacteria genome. 2. The catalytically inactive CRISPR nuclease of claim 1 for sequence-specific binding a yeast genome. 3. The catalytically inactive CRISPR nuclease of claim 1 for sequence-specific binding an isolated mammalian cell genome.
Assignees
Inventors
Classifications
- C12N9/22Primary
Ribonucleases {[RNase]; Deoxyribonucleases [DNase]} · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11214781B2 cover?
- The present disclosure provides a novel catalytically inactive MAD7 nuclease (dMAD7) that retains the ability to bind DNA in a sequence-specific manner. The MAD7 nuclease from which the dMAD7 has been derived was isolated from Eubacterium rectale.
- Who is the assignee on this patent?
- Inscripta Inc
- What technology area does this patent fall under?
- Primary CPC classification C12N9/22. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).